Arrowhead outlines REDEMPLO expansion with $60,000 annual price and expects top-line SHASTA-3/4 data in Q3 2026 [Seeking Alpha]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Seeking Alpha
Dr. Christopher Anzalone, CEO, announced Arrowhead's first FDA approval for REDEMPLO, marking a major milestone as the company transitions to a commercial-stage entity. He stated that "REDEMPLO is the first and only FDA-approved siRNA medicine for Quick Insights It marks Arrowhead's transition to a commercial-stage company but is not expected to materially affect financial results in fiscal 2026. The company is leveraging this launch alongside a unified pricing and patient support, with high expectations for best-in-class uptake. Ongoing SHASTA-3/4 Phase III trials, expanding indications for REDEMPLO, new clinical assets (zodasiran, ARO-DIMER-PA), and major collaborations including Novartis (with significant milestone payments) are primary growth drivers. Management expects its cash runway to extend into fiscal 2028, revenue is now dominated by licenses and collaborations, and there are challenges in demonstrating clinical benefit in SHASTA trials, with no substantial impact
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Novartis (NYSE:NVS) had its "buy (b)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Novartis (NYSE:NVS) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- Janux dives as gaps in prostate cancer study data worry investors [Yahoo! Finance Canada]Yahoo! Finance Canada
- Progress In Fight Against Malaria, As New Treatment Shows Promise [Forbes]Forbes
- Novartis (NYSE:NVS) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NVS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from MarketBeat
NVS
Earnings
- 10/28/25 - Miss
NVS
Sec Filings
- 11/25/25 - Form 6-K
- 11/20/25 - Form 6-K
- 11/5/25 - Form 6-K
- NVS's page on the SEC website